Hengrui Pharmaceuticals' Ivarmacitinib Approved for Rheumatoid Arthritis in China
CompanyDrug

Hengrui Pharmaceuticals’ Ivarmacitinib Approved for Rheumatoid Arthritis in China

Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services
CompanyDeals

Chinese Firms Nanjing F&S and Hunan Huize Form Alliance for Full-Process Pharma Services

Huapont Life Sciences Gains NMPA Approval for Generic Daivobet
CompanyDrug

Huapont Life Sciences Gains NMPA Approval for Generic Daivobet

Annoroad Gene Technology Files for IPO in Hong Kong
CompanyDeals

Chinese IVD Firm Annoroad Gene Targets Global Expansion with IPO

Ascletis Pharma's ASC30 Shows Positive Results in US Phase Ib Obesity Study
CompanyDrug

Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study

Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights
CompanyDeals

Abbisko Therapeutics Secures $85M from Merck for Pimicotinib Global Rights

Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong
CompanyDeals

Chia Tai Tianqing Launches NPP for Urgent Cancer Treatment in Hong Kong

Innovent Biologics' IBI363 Granted Breakthrough Therapy Designation for Melanoma
CompanyDrug

Innovent Biologics’ IBI363 Granted Breakthrough Therapy Designation for Melanoma

NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown
HospitalPolicy / Regulatory

NHC Data Reveals Digital Leap for Class 3 Hospitals Amid Drug Cost Crackdown

Hengrui's HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy
CompanyDrug

Hengrui’s HRS-5965 Granted Breakthrough Therapy Designation for IgA Nephropathy

Sanofi's Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease
CompanyDrug

Sanofi’s Dupixent Approved in Japan for Chronic Obstructive Pulmonary Disease

Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation
CompanyDeals

Pacific Shuanglin Bio-pharmacy Partners with XtalPi for Blood Product Innovation